MX2017007941A - Anticuerpos antagonistas anti-axl. - Google Patents

Anticuerpos antagonistas anti-axl.

Info

Publication number
MX2017007941A
MX2017007941A MX2017007941A MX2017007941A MX2017007941A MX 2017007941 A MX2017007941 A MX 2017007941A MX 2017007941 A MX2017007941 A MX 2017007941A MX 2017007941 A MX2017007941 A MX 2017007941A MX 2017007941 A MX2017007941 A MX 2017007941A
Authority
MX
Mexico
Prior art keywords
axl
antagonistic antibodies
antibodies
antagonistic
gas6
Prior art date
Application number
MX2017007941A
Other languages
English (en)
Inventor
Kiprijanov Sergej
Robert Micklem David
Hodneland NILSSON Linn
Ahmed Lavina
Bradley Lorens James
Sandal Tone
Original Assignee
Bergenbio Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bergenbio Asa filed Critical Bergenbio Asa
Publication of MX2017007941A publication Critical patent/MX2017007941A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Abstract

Se describen anticuerpos que se unen específicamente a la proteína Axl e inhiben la interacción entre Axl y el ligando Axl, Gas6. También se describen los métodos para la producción y uso de los anticuerpos anti-Axl.
MX2017007941A 2014-12-18 2015-12-18 Anticuerpos antagonistas anti-axl. MX2017007941A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201422605 2014-12-18
PCT/EP2015/080654 WO2016097370A2 (en) 2014-12-18 2015-12-18 Anti-axl antagonistic antibodies

Publications (1)

Publication Number Publication Date
MX2017007941A true MX2017007941A (es) 2018-01-30

Family

ID=55080088

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007941A MX2017007941A (es) 2014-12-18 2015-12-18 Anticuerpos antagonistas anti-axl.

Country Status (9)

Country Link
US (3) US10208121B2 (es)
EP (1) EP3233119A2 (es)
JP (2) JP6931609B2 (es)
KR (1) KR102453227B1 (es)
CN (2) CN116410318A (es)
AU (1) AU2015366213B2 (es)
CA (1) CA2969879A1 (es)
MX (1) MX2017007941A (es)
WO (1) WO2016097370A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410826D0 (en) 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
GB201410825D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
WO2016097370A2 (en) * 2014-12-18 2016-06-23 Bergen Teknologioverføring As Anti-axl antagonistic antibodies
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201509338D0 (en) * 2015-05-29 2015-07-15 Bergenbio As Combination therapy
GB201610902D0 (en) 2016-06-22 2016-08-03 Bergen Teknologioverforing As And Bergenbio As Anti-Axl Antagonistic Antibodies
KR20200029469A (ko) * 2017-07-18 2020-03-18 쿄와 기린 가부시키가이샤 항인간 ccr1 모노클로날 항체
EA202092448A1 (ru) * 2018-04-10 2021-03-05 Генмаб А/С Axl-специфичные антитела для лечения онкологических заболеваний
JP2021523379A (ja) 2018-05-14 2021-09-02 ベルゲンビオ アーエスアー 血清バイオマーカー
CN110540592B (zh) * 2018-05-29 2022-08-09 杭州尚健生物技术有限公司 结合axl蛋白的抗体及其应用
CN109206490A (zh) * 2018-09-29 2019-01-15 未名生物医药有限公司 蛋白序列11b09及其用途
CN109206489A (zh) * 2018-09-29 2019-01-15 未名生物医药有限公司 蛋白序列12g12及其用途
EP3946453A4 (en) * 2019-03-29 2022-12-07 Celldex Therapeutics, Inc. ANTI-AXL ANTIBODIES AND THEIR METHODS OF USE
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
WO2021154156A1 (en) * 2020-01-31 2021-08-05 Agency For Science, Technology And Research Anti-axl antibody and uses thereof
KR20220148237A (ko) 2020-02-28 2022-11-04 심포젠 에이/에스 항-axl 항체 및 조성물
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
WO2021204713A1 (en) 2020-04-08 2021-10-14 Bergenbio Asa Axl inhibitors for antiviral therapy
GB202006072D0 (en) 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
WO2022133169A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
GB202104037D0 (en) 2021-03-23 2021-05-05 Bergenbio Asa Combination therapy

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
US8933202B2 (en) * 2007-11-12 2015-01-13 U3 Pharma Gmbh AXL antibodies
BRPI0820543A2 (pt) 2007-11-15 2015-06-16 Chugai Pharmaceutical Co Ltd Anticorpo monoclonal capaz de ligar a anexelekto, e uso do mesmo
KR20120035145A (ko) 2009-05-11 2012-04-13 우드라이 파마 게엠베하 인간화 ａｘｌ 항체
WO2011014457A1 (en) 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments
MX336001B (es) * 2010-06-18 2016-01-07 Genentech Inc Anticuerpos anti-axl y metodos de uso.
KR101532210B1 (ko) 2011-05-06 2015-06-29 중산 호스피탈 푸단 유니버시티 플라즈마 마크로알엔에이로 구성된 간암 진단 마커 및 간암 진단의 새로운 방법
BR112013032899A2 (pt) 2011-06-22 2017-01-24 Inserm Inst Nat De La Santé Et De La Rech Médicale anticorpos anti-axl e utilizações dos mesmos
JP6033293B2 (ja) 2011-06-22 2016-11-30 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） 抗Ａｘｌ抗体及びその使用
EP2589609A1 (en) * 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
US9879061B2 (en) * 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
IN2015DN00188A (es) 2012-06-29 2015-06-12 Mitsubishi Gas Chemical Co
CN104955842B (zh) * 2012-11-05 2018-04-10 皮埃尔法布雷医药公司 抗原结合蛋白及其作为定位产品用于治疗癌症的用途
GB201410826D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
GB201410825D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
US9986723B2 (en) * 2014-10-22 2018-06-05 The Board Of Regents Of The University Of Texas System Screen and use of therapeutics for pancreatic ductal adenocarcinoma
WO2016097370A2 (en) * 2014-12-18 2016-06-23 Bergen Teknologioverføring As Anti-axl antagonistic antibodies
GB201610902D0 (en) * 2016-06-22 2016-08-03 Bergen Teknologioverforing As And Bergenbio As Anti-Axl Antagonistic Antibodies

Also Published As

Publication number Publication date
US20190177419A1 (en) 2019-06-13
CN116410318A (zh) 2023-07-11
AU2015366213A1 (en) 2017-06-22
US20170349658A1 (en) 2017-12-07
US10208121B2 (en) 2019-02-19
KR20170099918A (ko) 2017-09-01
JP6931609B2 (ja) 2021-09-08
JP2021101707A (ja) 2021-07-15
CA2969879A1 (en) 2016-06-23
WO2016097370A2 (en) 2016-06-23
AU2015366213B2 (en) 2021-10-07
CN107531786B (zh) 2023-01-13
US11584796B2 (en) 2023-02-21
CN107531786A (zh) 2018-01-02
WO2016097370A3 (en) 2016-08-11
EP3233119A2 (en) 2017-10-25
JP2018506961A (ja) 2018-03-15
KR102453227B1 (ko) 2022-10-11
US20230406941A1 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
MX2017007941A (es) Anticuerpos antagonistas anti-axl.
PH12016501763A1 (en) Multispecific antibodies
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
MX2016016886A (es) Anticuerpos anti-axl.
PH12016501894B1 (en) Anti-ox40 antibodies and methods of use
PH12017500322A1 (en) Anti-her2 antibodies and immunoconjugates
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
MX2017003022A (es) Anticuerpos anti-cll-1 e inmunoconjugados.
MX2016016883A (es) Anticuerpo anti-axl.
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
MX2016016881A (es) Anticuerpos que se unen a axl.
LT3113797T (lt) Antikūnai, panaudojimai ir būdai
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
MX2016004853A (es) Metodos de uso de anticuerpos anti-ly6e.
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
MX2017000527A (es) Formulaciones de anticuerpos cristalinos.
MX2021006003A (es) Formulaciones de anticuerpos cristalinos.
EP3194448A4 (en) Anti-vasa antibodies, and methods of production and use thereof
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
MX2015010789A (es) Anticuerpos anti-pcsm.
NZ744340A (en) Anti-jagged1 antibodies and methods of use
TH1501005368A (th) สารเตรียมเชิงซ้อนที่รวมถึง วัลซาร์แทน และ โรซูวาสแตติน แคลเซียม และ วิธีการผลิต สำหรับสิ่งนั้น